Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2013-09-18 (12 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: CACHAN (94230), Val-de-Marne
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE TCHAPARIAN SELARL : revenue, balance sheet and financial ratios
PHARMACIE TCHAPARIAN SELARL is a French company
founded 12 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in CACHAN (94230),
this company of category PME
shows in 2022 a revenue of 1.2 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE TCHAPARIAN SELARL (SIREN 797477445)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
1 202 716 €
N/C
N/C
N/C
N/C
N/C
N/C
Net income
22 238 €
-17 460 €
100 603 €
92 946 €
35 163 €
49 393 €
24 959 €
25 832 €
35 321 €
EBITDA
N/C
N/C
119 663 €
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
8.4%
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, PHARMACIE TCHAPARIAN SELARL generates positive net income of 22 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 35 k€ -> 22 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
22 238 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 5%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 74%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
4.98%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
73.929%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
185.486
143.977
128.454
89.79
66.923
40.261
22.653
14.983
4.98
Financial autonomy
28.464
32.816
36.149
42.901
48.073
53.412
64.742
68.744
73.929
Repayment capacity
None
None
None
None
None
None
0.957
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
9.274%
None%
None%
Sector positioning
Debt ratio
4.982024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Excellent
In 2024, the debt ratio of PHARMACIE TCHAPARIAN SELARL (4.98) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
73.93%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Excellent+6 pts over 3 years
In 2024, the financial autonomy of PHARMACIE TCHAPARIAN SELARL (73.9%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
0.96 years2022
2022
Q1: 1.29 years
Med: 3.55 years
Q3: 6.63 years
Excellent
In 2022, the repayment capacity of PHARMACIE TCHAPARIAN SELARL (0.96) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 142.21. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
142.925
142.541
145.089
141.727
132.812
150.376
194.309
156.632
142.208
Interest coverage
None
None
None
None
None
None
1.364
None
None
Sector positioning
Liquidity ratio
142.212024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Average-17 pts over 3 years
In 2024, the liquidity ratio of PHARMACIE TCHAPARIAN SELARL (142.21) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
1.36x2022
2022
Q1: 0.74x
Med: 2.5x
Q3: 5.15x
Average
In 2022, the interest coverage of PHARMACIE TCHAPARIAN SELARL (1.4x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE TCHAPARIAN SELARL
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
95 303 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
31
0
0
Customer payment term (days)
0
0
0
0
0
0
2
0
0
Supplier payment term (days)
0
0
0
0
0
0
50
0
0
Positioning of PHARMACIE TCHAPARIAN SELARL in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE TCHAPARIAN SELARL is estimated at
310 458 €
(range 216 198€ - 464 464€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
216k€310k€464k€
310 458 €Range: 216 198€ - 464 464€
NAF 5 année 2024
Valuation method used
Net Income Multiple
22 238 €
×
14.0x
=310 459 €
Range: 216 199€ - 464 464€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE TCHAPARIAN SELARL with other companies in the same sector:
Frequently asked questions about PHARMACIE TCHAPARIAN SELARL
What is the revenue of PHARMACIE TCHAPARIAN SELARL ?
The revenue of PHARMACIE TCHAPARIAN SELARL in 2022 is 1.2 M€.
Is PHARMACIE TCHAPARIAN SELARL profitable?
Yes, PHARMACIE TCHAPARIAN SELARL generated a net profit of 22 k€ in 2024.
Where is the headquarters of PHARMACIE TCHAPARIAN SELARL ?
The headquarters of PHARMACIE TCHAPARIAN SELARL is located in CACHAN (94230), in the department Val-de-Marne.
Where to find the tax return of PHARMACIE TCHAPARIAN SELARL ?
The tax return of PHARMACIE TCHAPARIAN SELARL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE TCHAPARIAN SELARL operate?
PHARMACIE TCHAPARIAN SELARL operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart